1 results match your criteria: "France fHZRM - Hemophilia Centre Rhein Main[Affiliation]"
Challenges of the management of severe hemophilia A with inhibitors: two case reports emphasizing the potential interest of a high-purity human Factor VIII/von Willebrand factor concentrate and individually tailored prophylaxis guided by thrombin-generation test.
Blood Coagul Fibrinolysis
December 2015
aHematology and Oncology Pediatric Unit, CHU Saint Etienne bHematology Laboratory, CHU Caremeau, Nimes cResearch Unit on Hemophilia, UFR Laennec dClinical Hemostasis Unit, Hôpital Edouard Herriot, Lyon eHemostasis Laboratory, CHU, Saint Etienne, France fHZRM - Hemophilia Centre Rhein Main, Frankfurt-Mörfelden, Germany.
Severe hemophilia A is an X-linked bleeding disorder. Immune tolerance induction (ITI) is the best strategy of treatment when patients develop inhibitors. The objective is to illustrate the benefit of a high-purity human factor VIII/von Willebrand factor (VWF) concentrate (Octanate) in the management of ITI.
View Article and Find Full Text PDF